Sumit Jamwal, PhD
Associate Research ScientistAbout
Research
Publications
2026
Half a century of pneumococcal vaccination in sickle cell disease: Are we winning the battle or losing immunity?
Jamwal S, Omene B, Giri A, Rojas K, Mohanty S, Calhoun C, Krishnamurti L, Montgomery R, Shaw A, Andemariam B, Yildirim I. Half a century of pneumococcal vaccination in sickle cell disease: Are we winning the battle or losing immunity? Vaccine 2026, 88: 128866. PMID: 42322679, DOI: 10.1016/j.vaccine.2026.128866.Peer-Reviewed Original ResearchPneumococcal conjugate vaccineInvasive pneumococcal diseaseSickle cell diseasePneumococcal diseaseImmunological deficitsSerotype coverageConjugate vaccineRates of invasive pneumococcal diseaseEvolving epidemiologyCell diseaseContext of sickle cell diseaseVaccine-type invasive pneumococcal diseaseEpidemiology of pneumococcal diseaseNon-vaccine serotypesPneumococcal polysaccharide vaccineEvidence-based vaccination strategiesPersistent disease burdenPenicillin prophylaxisImmunocompromised populationsPneumococcal infectionClinical efficacyVaccine approachesSerotype replacementPneumococcal vaccinePolysaccharide vaccineAdaptive Immune Remodeling in Sickle Cell Disease: Linking Hemolysis-Driven Inflammation to Immune Dysfunction
Jamwal S, Mohanty S, Calhoun C, Krishnamurti L, Montgomery R, Shaw A, Yildirim I. Adaptive Immune Remodeling in Sickle Cell Disease: Linking Hemolysis-Driven Inflammation to Immune Dysfunction. Experimental Hematology 2026, 160: 105459. PMID: 42219144, DOI: 10.1016/j.exphem.2026.105459.Peer-Reviewed Original ResearchSickle cell diseaseDamage-associated molecular patternsImmune remodelingImmune dysfunctionHelper T cell polarizationAdaptive immunityMemory B cell compartmentCell diseaseTransfusion-related alloimmunizationImpaired vaccine responsesB cell compartmentBone marrow nicheT cell activationInnate immune activationAdult SCD populationT cell polarizationGerminal center dynamicsSusceptibility to infectionProgenitor cell fatePersistent hemolysisHematopoietic stemMarrow nicheImmune activationVaccine responseChronic inflammation
2025
Unravelling the Immunological Enigma of Sickle Cell Disease: Current Understanding and Future Directions
Jamwal S, Calhoun C, Mohanty S, Montgomery R, Krishnamurti L, Shaw A, Yildirim I. Unravelling the Immunological Enigma of Sickle Cell Disease: Current Understanding and Future Directions. Immunology 2025, 177: 445-456. PMID: 41387179, PMCID: PMC12826409, DOI: 10.1111/imm.70080.Peer-Reviewed Reviews, Practice Guidelines, Standards, and Consensus StatementsMemory B cellsSickle cell diseaseImmune dysregulationT cellsB cellsChronic inflammationImmunological enigmaImmune activationClass-switched memory B cellsAntigen-specific T cell responsesAntigen-specific T cellsImmune responseCell diseaseAntigen-specific immune activationAntigen-specific immune responsesImmune-targeted therapiesSickle cell disease patientsT-cell countsT-cell abnormalitiesT-cell phenotypeMemory B cell differentiationT cell responsesB cell compartmentAdaptive immune dysfunctionSickle cell disease pathophysiology
2024
A review on polyamines as promising next-generation neuroprotective and anti-aging therapy
Arthur R, Jamwal S, Kumar P. A review on polyamines as promising next-generation neuroprotective and anti-aging therapy. European Journal Of Pharmacology 2024, 978: 176804. PMID: 38950837, DOI: 10.1016/j.ejphar.2024.176804.Peer-Reviewed Reviews, Practice Guidelines, Standards, and Consensus StatementsCognitive dysfunctionNeurodegenerative disordersRegulation of gene expressionProgressive degeneration of neuronsProgrammed Cell DeathDegeneration of neuronsSymptomatic therapyPharmacological strategiesAnti-oxidative effectsAnti-aging therapyAverage ageProgressive degenerationNeuroprotective effectsLocomotor abnormalitiesIon channelsCell deathBiochemical activityGene expressionPopulation average ageTherapyMolecular mechanismsDisordersPolyamine supplementationDysfunctionAnti-aging effectsDopamine Transporter Deficiency Syndrome (DTDS)
Jamwal S, Gautam A. Dopamine Transporter Deficiency Syndrome (DTDS). 2024, 1-4. DOI: 10.1007/978-3-319-66816-1_452-1.BooksDopamine transporter deficiency syndromeDopamine transporterMovement disordersHuman dopamine transporterSLC6A3 geneBehavioral symptomsAmbiguous eventsEarly adolescenceSlow speechDisordersHyperkinetic movementsSLC6A3Choreiform movementsAdolescentsEarly childhoodAssociated with poor outcomesLater onsetHypokinetic movementsAffected individualsNon-specific symptomsSymptomsDevelopmental targetsEarly-onsetResting tremorRecurrent movement disordersNutraceuticals Unveiled a Multifaceted Neuroprotective Mechanisms for Parkinson’s Disease: Elixir for the Brain
Soni D, Jamwal S, Chawla R, Singh S, Singh D, Singh T, Khurana N, Kanwal A, Dureja H, Patil U, Singh R, Kumar P. Nutraceuticals Unveiled a Multifaceted Neuroprotective Mechanisms for Parkinson’s Disease: Elixir for the Brain. Food Reviews International 2024, 40: 3079-3102. DOI: 10.1080/87559129.2024.2337766.Peer-Reviewed Reviews, Practice Guidelines, Standards, and Consensus StatementsPre-clinicalGut-brain axisProtein ubiquitinationParkinson's diseaseMitochondrial dysfunctionSignaling pathwayMolecular mechanismsRelieve PD symptomsSymptoms of PDClinical trialsHealth benefits of nutraceuticalsBenefits of nutraceuticalsCustomized therapyClinical aspectsExpression of PDMediterranean dietNeurotransmitter imbalanceNeuroprotective mechanismsNeuroprotective potentialOxidative stressDiseasePD symptomsHealth benefitsSymptomsUbiquitin
2023
Bacillus Calmette–Guérin Vaccine Attenuates Haloperidol-Induced TD-like Behavioral and Neurochemical Alteration in Experimental Rats
Yedke N, Upadhayay S, Singh R, Jamwal S, Ahmad S, Kumar P. Bacillus Calmette–Guérin Vaccine Attenuates Haloperidol-Induced TD-like Behavioral and Neurochemical Alteration in Experimental Rats. Biomolecules 2023, 13: 1667. PMID: 38002349, PMCID: PMC10669047, DOI: 10.3390/biom13111667.Peer-Reviewed Original ResearchConceptsBCG vaccineTardive dyskinesiaOrofacial dyskinesiaNeurotransmitter levelsBacillus Calmette-Guérin (BCG) vaccineFirst-generation antipsychotic drugsManagement of TDOxidative stressLevels of HVACalmette-Guérin vaccineHyperkinetic movement disordersMajor pathophysiological mechanismsPro-apoptotic markersLong-term useBCG treatmentNeuroprotective effectsNeurochemical alterationsOrofacial dysfunctionPathophysiological mechanismsAntipsychotic medicationNeuromodulatory propertiesSuppress inflammationSingle administrationAntipsychotic drugsHaloperidol injectionAge-associated sex difference in the expression of mitochondria-based redox sensitive proteins and effect of pioglitazone in nonhuman primate brain
Jamwal S, Blackburn J, Elsworth J. Age-associated sex difference in the expression of mitochondria-based redox sensitive proteins and effect of pioglitazone in nonhuman primate brain. Biology Of Sex Differences 2023, 14: 65. PMID: 37770961, PMCID: PMC10540392, DOI: 10.1186/s13293-023-00551-6.Peer-Reviewed Original ResearchConceptsSubstantia nigraSex-dependent expressionPrimate brainAdult male monkeysCerebrospinal fluidMale monkeysPeroxisome proliferator-activated receptor gamma agonistProliferator-activated receptor gamma agonistsEffect of pioglitazoneWeeks of treatmentReceptor gamma agonistsGreater expressionAdult female monkeysNonhuman primate brainNovel neuroprotective treatmentAfrican green monkeysSex-based differencesOral pioglitazoneNeuroprotective treatmentPIO treatmentRisk factorsCNS disordersGamma agonistsPreclinical studiesParkinson's diseaseAnimal models of Huntington’s disease and their applicability to novel drug discovery and development
Upadhayay S, Jamwal S, Kumar P. Animal models of Huntington’s disease and their applicability to novel drug discovery and development. Expert Opinion On Drug Discovery 2023, 18: 527-538. PMID: 37042034, DOI: 10.1080/17460441.2023.2201493.Peer-Reviewed Reviews, Practice Guidelines, Standards, and Consensus StatementsConceptsHD animal modelsAnimal modelsHuntington's diseaseNon-motor symptomsProgressive neurodegenerative disorderDrug therapyDisease progressionPreclinical phaseLoss of functionNeurodegenerative disordersClinical phaseDrug discoveryDiseaseNovel drug discoveryHuntingtin geneToxic gainCAG trinucleotide repeatDrugsProgressionHD geneEnormous progressionAn Overview of the Pathophysiological Mechanisms of 3-Nitropropionic Acid (3-NPA) as a Neurotoxin in a Huntington's Disease Model and Its Relevance to Drug Discovery and Development
Upadhayay S, Yedke N, Rahi V, Singh S, Kumar S, Arora A, Chandolia P, Kaur P, Kumar M, Koshal P, Jamwal S, Kumar P. An Overview of the Pathophysiological Mechanisms of 3-Nitropropionic Acid (3-NPA) as a Neurotoxin in a Huntington's Disease Model and Its Relevance to Drug Discovery and Development. Neurochemical Research 2023, 48: 1631-1647. PMID: 36738367, DOI: 10.1007/s11064-023-03868-1.Peer-Reviewed Reviews, Practice Guidelines, Standards, and Consensus StatementsConceptsMedium spiny neuronsAnimal modelsGABAergic medium spiny neuronsDisease modelsKey clinical manifestationsHuntington's disease modelsPathogenesis of diseaseWeb of ScienceClinical manifestationsPathophysiological mechanismsSpiny neuronsPreclinical studiesMotor impairmentLike symptomsTherapeutic targetExperimental animalsExcessive productionHuntington's diseaseOxidative stressDiseasePathogenic conditionsDrug discoveryMitochondrial functionFree radicalsNeurotoxin
Get In Touch
Contacts
Mailing Address
Yale School of Medicine
Suite 901, 300 George St.
New Haven, CT 06511
United States